DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment

 

Oncology Homepage

Community engagement interventions may reduce disparities in lung cancer outcomes among minorities

ACGT awards $1.3 million to scientists working to cure glioblastoma, sarcoma and ovarian cancer

AbbVie and Harpoon Therapeutics announce immuno-oncology research collaboration

Xstrahl has received FDA clearance for the marketing of its latest skin cancer therapy device

Early clinical data suggests nearly 2X prolonged median survival for inoperable, locally advanced pancreatic cancer with MRIdian

UZ Leuven treats first patient in Europe on Varian Halcyon cancer treatment system

OncLive adds George Washington Cancer Center to its Strategic Alliance Partnership program

Children’s Hospital Los Angeles and Keck Medicine of USC develop liquid biopsy for retinoblastoma

CSA Medical to feature the Rapid AV catheter and discuss truFreeze clinical studie at American College of Gastroenterology (ACG)

Workers at smaller companies less likely to be screened for cancer

FDA’s Pazdur outlines how Oncology Center of Excellence will promote collaboration

Press releases may be edited for formatting or style
CRANBURY, N.J.--(BUSINESS WIRE)--During his 18 years at FDA, Richard Pazdur, MD, has worked to balance the needs of patients anxious for new cancer cures with the agency’s standards that protect them from harm. In January, Pazdur took on a new role—director of the new Oncology Center of Excellence (OCE), which was borne of the National Cancer Moonshot’s call for greater collaboration among those charged with speeding the arrival of new cancer-fighting products.

Pazdur outlines how OCE will function—and how it bring a stronger patient voice to FDA’s decisions—in a special issue of Evidence-Based Oncology,™ (EBO™); the issue features coverage from the spring 2017 Oncology Stakeholders’ Summit, which focused on regulatory issues.

Story Continues Below Advertisement

Inspiring a Better Healthcare System- We are the new Change Healthcare

Last spring the majority of McKesson Technology Solutions and Change Healthcare came together, forming a new health IT company with one focus - inspiring a better healthcare system. Click above to learn more.



“This new center leverages the combined skills of regulatory scientists and reviewers with oncology clinical expertise across the FDA, emulating the multidisciplinary organizational model of academia and cancer care centers and building on the integrative approach to medical product development that the agency’s broader oncology community has embraced over the past decade,” Pazdur writes.

Since 2005, when he became director of the Office of Hematology and Oncology Products (OHOP) within FDA, Pazdur has overseen the arrival of faster pathways to approval, which tracked the rise of new treatment methods, including immunotherapy. As he explains, OCE builds on that record but with some key additions. “An important aim of the OCE is to facilitate incorporation of the patient view into regulatory decision-making,” he writes.

A key feature of the OCE calls for new submissions to head to a clinical review team that draws from three medical product centers. The team will make recommendations, which will head to Pazdur for review and sign-off. Other aspects of FDA review remain with their traditional centers, he explains. The OCE will embrace new trial designs, with the goal of making research simpler and requiring fewer data points.

“These initiatives will allow us to expedite drug development and approval of truly novel agents that will have a major impact on our patients, while allowing us to make thoughtful decisions regarding the risk-benefit of oncology drugs,” Pazdur writes.

Pazdur remains the acting director of OHOP while taking on his new role.

About The American Journal of Managed Care®:

The American Journal of Managed Care® (AJMC®) is a peer-reviewed, MEDLINE-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care® and two evidence-based series, Evidence-Based Oncology™ and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Dr. Jeff Prescott at (609) 716-7777, x331.

Back to HCB News
  Pages: 1

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED